Lila Adnane

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

J. Llovet, S. Wilhelm, Lila Adnane, 2008, Molecular Cancer Therapeutics.

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

D. Auclair, P. Vincent, G. Bollag, 2004, Cancer Research.

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

S. Wilhelm, Lila Adnane, I. Taylor, 2006, Methods in enzymology.

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

D. Zopf, K. Thierauch, S. Wilhelm, 2011, International journal of cancer.

Receptor Tyrosine Kinases Involved in Tumor Progression Activity and Targets the RAF/MEK/ERK Pathway and BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor

D. Auclair, P. Vincent, G. Bollag, 2004 .

Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9

Lila Adnane, A. Voznesensky, P. Trail, 2011, Molecular Cancer Therapeutics.

Recent advances in the research and development of RAF kinase inhibitors.

S. Wilhelm, Lila Adnane, J. Dumas, 2006, Current topics in medicinal chemistry.

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

D. Auclair, P. Vincent, G. Bollag, 2004, Cancer Research.